Filing Flows › Cytokinetics (CYTK) › Guidance history
Cytokinetics (CYTK) guidance history: what it guided and what it reported
Cytokinetics gave guidance in 9 earnings releases on file since Feb 27, 2024. Its releases raised guidance twice and lowered it 0 times.
Operating expenses
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2024 | $420M–$450M (Feb 27, 2024) | — | — | — |
Stock-based compensation
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $120M–$130M (Feb 24, 2026) → reaffirmed $120M–$130M (May 5, 2026) → raised $130M–$140M (Nov 4, 2026) | — | to be reported | — |
| FY2025 | $110M–$120M (Feb 27, 2025) → reaffirmed $110M–$120M (May 6, 2025) → reaffirmed $110M–$120M (Aug 7, 2025) → reaffirmed $110M–$120M (Nov 5, 2025) | — | — | — |
The latest quarter
Cytokinetics, Q3 2026: revenue $47.6M (25× year over year), operating margin -351.3%, net loss $190M, operating cash flow −$124M. The chart follows the revenue to costs, profit and cash.
Questions
Does Cytokinetics beat its guidance?
Cytokinetics gave guidance in 9 earnings releases on file since Feb 27, 2024. Its releases raised guidance twice and lowered it 0 times.
How often does Cytokinetics raise guidance?
Its earnings releases raised guidance twice and lowered it 0 times since Feb 27, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.